BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 549 filers reported holding BIO-TECHNE CORP in Q1 2022. The put-call ratio across all filers is 0.27 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $96,102,860 | -16.9% | 1,411,824 | -0.4% | 0.03% | -15.2% |
| Q2 2023 | $115,683,097 | +10.7% | 1,417,164 | +0.6% | 0.03% | +3.1% |
| Q1 2023 | $104,506,779 | -9.8% | 1,408,637 | +0.7% | 0.03% | -13.5% |
| Q4 2022 | $115,921,521 | +20.6% | 1,398,667 | +313.3% | 0.04% | +8.8% |
| Q3 2022 | $96,105,000 | -16.0% | 338,396 | +2.5% | 0.03% | -15.0% |
| Q2 2022 | $114,422,000 | -17.1% | 330,088 | +3.6% | 0.04% | -2.4% |
| Q1 2022 | $137,974,000 | -13.4% | 318,616 | +3.5% | 0.04% | -12.8% |
| Q4 2021 | $159,265,000 | +10.4% | 307,851 | +3.4% | 0.05% | 0.0% |
| Q3 2021 | $144,264,000 | +43.3% | 297,715 | +33.2% | 0.05% | +42.4% |
| Q2 2021 | $100,670,000 | +20.6% | 223,581 | +2.3% | 0.03% | +6.5% |
| Q1 2021 | $83,465,000 | +13.3% | 218,533 | -5.8% | 0.03% | +6.9% |
| Q4 2020 | $73,695,000 | +30.4% | 232,071 | +1.7% | 0.03% | +11.5% |
| Q3 2020 | $56,512,000 | -5.1% | 228,116 | +1.1% | 0.03% | -10.3% |
| Q2 2020 | $59,576,000 | +27.7% | 225,604 | -8.3% | 0.03% | +7.4% |
| Q1 2020 | $46,660,000 | -12.7% | 246,066 | +1.0% | 0.03% | -6.9% |
| Q4 2019 | $53,462,000 | +17.9% | 243,551 | +5.1% | 0.03% | +7.4% |
| Q3 2019 | $45,363,000 | +0.6% | 231,834 | +7.2% | 0.03% | 0.0% |
| Q2 2019 | $45,089,000 | +8.1% | 216,263 | +3.0% | 0.03% | 0.0% |
| Q1 2019 | $41,695,000 | +40.6% | 209,994 | +2.5% | 0.03% | +17.4% |
| Q4 2018 | $29,657,000 | -28.8% | 204,926 | +0.4% | 0.02% | -17.9% |
| Q3 2018 | $41,647,000 | +2.8% | 204,041 | -25.5% | 0.03% | -3.4% |
| Q2 2018 | $40,496,000 | +8.4% | 273,708 | +10.6% | 0.03% | 0.0% |
| Q1 2018 | $37,368,000 | +39.7% | 247,403 | +19.8% | 0.03% | +38.1% |
| Q4 2017 | $26,754,000 | +12.2% | 206,510 | +4.7% | 0.02% | 0.0% |
| Q3 2017 | $23,838,000 | +10.2% | 197,184 | +7.1% | 0.02% | +5.0% |
| Q2 2017 | $21,633,000 | +19.1% | 184,110 | +3.0% | 0.02% | +11.1% |
| Q1 2017 | $18,162,000 | +7.3% | 178,663 | +8.6% | 0.02% | -5.3% |
| Q4 2016 | $16,921,000 | +0.6% | 164,544 | +7.2% | 0.02% | -5.0% |
| Q3 2016 | $16,812,000 | +5.3% | 153,527 | +8.4% | 0.02% | 0.0% |
| Q2 2016 | $15,967,000 | +24.1% | 141,588 | +4.0% | 0.02% | +17.6% |
| Q1 2016 | $12,870,000 | +9.7% | 136,160 | +4.5% | 0.02% | +6.2% |
| Q4 2015 | $11,730,000 | +2.1% | 130,332 | +4.8% | 0.02% | -5.9% |
| Q3 2015 | $11,494,000 | +1.4% | 124,310 | +8.0% | 0.02% | +6.2% |
| Q2 2015 | $11,338,000 | +7.2% | 115,137 | +9.2% | 0.02% | +6.7% |
| Q1 2015 | $10,579,000 | +23.9% | 105,480 | +14.1% | 0.02% | +15.4% |
| Q4 2014 | $8,540,000 | – | 92,419 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Broadcrest Asset Management, LLC | 275,000 | $18,719,250 | 20.14% |
| Montanaro Asset Management Ltd | 408,800 | $27,827,016 | 4.90% |
| Sandhill Capital Partners LLC | 613,061 | $41,731,091 | 3.90% |
| Pembroke Management, LTD | 365,611 | $24,887,141 | 3.40% |
| DF DENT & CO INC | 3,349,047 | $227,969,648 | 3.34% |
| Brown Capital Management | 3,158,004 | $214,965,332 | 3.30% |
| Ownership Capital B.V. | 1,786,273 | $121,591,603 | 3.05% |
| STONE RUN CAPITAL, LLC | 86,335 | $5,876,823 | 2.88% |
| Jackson Square Partners, LLC | 1,260,547 | $85,805,434 | 2.87% |
| Summit Creek Advisors LLC | 284,681 | $19,378,236 | 2.64% |